The data behind an AI discovery platform
LinkedIn caption
📊 The data behind an AI discovery platform
Jim Flynn brought a data-centered investment perspective to ARDD 2026’s Full-Stack and Growth Stage Investor Panel. He described Deerfield’s approach as building around proprietary information, with software helping turn that information into useful research and development decisions.
💡 His contribution also addressed a practical constraint on AI learning: the pace of generating new experimental evidence. Molecular representation and slow synthesis cycles can limit how quickly small-molecule discovery systems test ideas and learn from the results.
The discussion extended to development strategy. Flynn noted that longevity investments increasingly begin with acute or orphan indications, and considered how university-originated targets could be combined with licensed assets. His remarks connected the quality of a company’s data with its route toward a concrete therapeutic program.
#ARDD2026 #DrugDiscovery
X caption
📊 Jim Flynn connected proprietary data, experimental learning cycles and practical first indications at #ARDD2026, asking what makes an AI-enabled drug discovery platform useful and distinctive. Distinctive data need to support useful research and development decisions.
Credit: Michael DeStefano
Copy and paste the caption manually, then attach the downloaded photo. Nothing is published automatically.
